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Summary This open-label, non-randomized, parallel-group trial investigated the pharmacokinetics of raltitrexed (Tomudex, formerly ZD1694)
after a single intravenous dose of 3.0 mg m-2, comparing eight cancer patients with mild to moderate renal impairment (creatinine clearance
25-65 ml min-') with eight cancer patients with normal renal function (creatinine clearance >65 ml min-'). The primary end points were area
under the plasma raltitrexed concentration-vime curve from the start of the infusion to the last determined concentration (AUCo_) and AUC
to infinity (AUCo); secondary end points were peak corncentrations of ralftitrexed (C,n,,) and elimination half-life (t,>). The groups were
compared statistically using analysis of covariance. The AUCs were greater for patients with renal impairment than for patients with normal
renal function (2452.2 compared with 1247.3 ng h ml-' forAUCo._. (ratio 1.97; 95% Cl 1.36-2.84); 2961.5 compared with 1457.0 ng h ml-' for
AUCo_ (ratio 2.03; 1.25-3.29). These differences were statistically significant (P= 0.002 and P = 0.008 forAUC,, and AUCo_ respectively.
Terminal half-life was longer for the renally impaired patients (271.2 compared with 143.3; P = 0.030). There was no significant statistical
difference between the groups for C,, (652.9 compared with 564.7 ng ml-' for patients with impaired and normal renal function respectively:
ratio 1.16; 0.91-1.46; P=0.204). There was a clear relationship between raltfitrexed clearance and creatinine clearance. Adverse events,
severe (WHO grade 3 or 4) toxicity and hospitalization due to adverse events were more frequent in the group with renal impairment.
Therefore, a reduction in ralftitrexed dose and increased interval between doses is recommended for patients with mild to moderate renal
impairment.
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Raltitrexed (Tomudex. ZD1694: Zeneca Limited) is a cytotoxic
agent w-hich acts by direct and specific inhibition of thymidydlate
synthase. the enzyme catalysing a critical step in de novo DNA
synthesis. i.e. the production of thymidine monophosphate from
deoxvuridine monophosphate. Some clinically effective anti-
cancer agents. such as 5-fluorouracil and methotrexate. act in part
by inhibiting thymidylate synthase but also have effects on other
enzyme pathways. xvhich may contribute to their anti-tumour
activity and obserned toxicity profiles.
Raltitrexed inhibits thymidylate synthase selectively in vitro
(Jackman et al. 1991). Preclinical studies showed that raltitrexed
enters cells rapidly usinc the reduced folate carrier. Once inside
cells. it is conxerted efficiently bv folhpolyglutamate svnthetase to
polyglutamated forms. which are markedlv more potent inhibitors
of thvymidylate synthase than the parent compound. The poly-
glutamates are retained in cells and cause prolonged inhibition of
th midvlate synthase. which leads to DNA fragmentation and cell
death. In humans. plasma concentrations of raltitrexed showed a
triphasic decline after administration by a single 15-min intra-
venous infusion. The mean apparent half-life of the terminal
(gamma) phase (tl, ,) was 50-lOO h (Clarke et al. 1996). This
prolonged t1,, may represent hydrolysis of the polvalutamated
Received 17 November 1997
Revised 4 Apnl 1998
Accepted 14 Apnl 1998
Correspondence to: IR Judson, CRC Centre for Cancer Therapeutics.
The Institute of Cancer Research. Block E. 15 Cotswold Road. Belmont.
Sutton. Surrey SM2 5NG. UK
forms and release of raltitrexed from tissues into the circulation.
and allows the druc to be administered as a single dose once ever
3 weeks.
In the phase I trial. a dose and schedule of 3.0mg m-' every 3
weeks was identified as suitable for phase H inxvestigation. Higher
doses w-ere associated with significant asthenia. and antiprolifera-
tixe toxicities. if thev occurred. showed a tendencv to be cumula-
tive. In phase H trials. intravenous raltitrexed at a dose of
3.0 mg m-' once everv 3 weeks produced objectixe responses in
several solid tumours including colorectal (Zalcberg et al. 1996).
breast (Smith et al. 1996). ovarian (Gore et al. 1995). pancreatic
(Pazdur et al. 1996) and non-small-cell lung cancer (Heaxen et al.
1994). In these trials. the safet) profile ofraltitrexed was consistent
with that expected for an active cvtotoxic agent of this class. As
predicted. the most frequentlI observed toxicities were asthenia.
diarrhoea. nausea and vomiting. leucopenia and reversible
increases in aspartate aminotransferase (AST) and/or alanine
aminotransferase (ALT). The most serious (life-threatenin) toxici-
ties were gyastrointestinal toxicitx and haematological suppression.
This open-label. non-randomized. parallel-group trial w-as
undertaken to determine the effect of mild to moderate renal
impairment on the pharmacokinetics of raltitrexed after adminis-
tration of a sinale intravenous dose of 3.0 mgr m-.
PATIENTS AND METHODS
Patients
The study was approved by the Research Ethics Committees ofthe
participating centres. Sixteen adult patients with adxanced solid
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tumours not amenable to curative therapy were recruited into the
trial. Eight of the patients had mild to moderate impairnrent of
renal function (defined as creatinine or [sICr]EDTA clearance
between 25 and 65 ml min-'), and eight had normal renal function
(creatinine or ["Cr]EDTA clearance > 65 ml min-'). Seven ofthe
eight patients with renal impairment were women and seven ofthe
patients with normnal renal function were men.
Other entry criteria included normal hepatic function, normal
marrow reserve. World Health Organization (WHO) performance
status score of 0-2 (WHO, 1979) and weight within 20% of the
Metropolitan Life normal weight for their height. Exclusion
criteria included the presence of third space fluid (ascites or
pleural effusion). treatment with any concomitant medication that
may affect renal function or cytotoxic chemotherapy less than 4
weeks before the trial. Patients were excluded if there was
evidence ofresidual toxicity from previous chemotherapy.
Trial _etment
Each patient received a single intravenous dose of 3.0 mg m-2
raltitrexed administered as a 15-min infusion, and was then moni-
tored for 28 days. Patients showing clinical benefit after this first
dose of raltitrexed could continue treatment at intervals of 3
weeks. In the event oftoxicity, treatment could be delayed by up to
3 weeks or the dose ofraltitrexed could be reduced.
Assessments
The patients remained in hospital for 48 h after the first dose of
raltitrexed and then returned at 1, 2, 3 and 4 weeks after dosing.
Patients who then continued raltitrexed treatment were seen
routinely at 3-week intervals for dosing and again 3 weeks after
the last dose.
Pharmacok*netcs
Raltitrexed pharmacokinetics were assessed after the first dose
only. Blood samples were collected before the first dose and at 5.
10 and 15 min (during the infusion) then and at 20, 25, 30. 45, 60
and 90 min. 2, 3, 5, 8, 12 and 24 h, and days 3, 8, 15, 22 and 29
after the first dose. Concentrations of raltitrexed in plasma were
measured using a radioimmunoassay by Zeneca Pharmaceuticals,
UK (Clarke et al, 1996). The limit of quantification of the assay
was 0.768 ng ml-.
The peak plasma concentration (C ) and the time toCn (tr,)
were calculated directly from raltitrexed concentration data The
area under the plasma concentration-time curve from the start of
the infusion to the time of the last determined concentration
(AUCO.,.) was calculated using the linear trapezoidal rule, by the
pharmacokinetic analysis program PHASAR (version 1.2). The
following pharmacokinetic parameters were calculated by fitting a
non-linear regression model to the data using the MODFIT data
analysis program (version 5): the AUC to infinity (AUCQ; the
volume ofthe central compartment (V) and volume at steady state
(V5s); (tl) and the terminal phase half-life (tIrr); and the clear-
ance, which was calculated by dividing the actual dose in mg by
the AUC,,. A three-compartment model with infusion input was
used with a weighting factor of I/concentration2 for 12 patients.
For four patients (two in each group), a weighting factor of
1/concentration (Clarke et al, 1996) was used to improve the fit
of the terminal phase as determined by the Akaike information
criteria of the data. The model also generated the microrate
constants for the transfer ofraltitrexed between the three compart-
ments and the microrate constant for elimination from the central
compartmwnt (data not reported, on file at Zeneca).
Safety
Adverse events were recorded at each visit. Any detimental
change in the patient's condition, excluding unequivocal cancer
progression, occurring between the start ofthe trial and the end of
the 3-week follow-up period after the last dose of raltitrexed was
considered to be an adverse event. The severity and duration of
each event, and its putative relationship to raltitrexed treatment.
were recorded. Standard clinical laboratory tests were performed
before each dose ofthedrug and at the final follow-up assessment.
An electrocardiogram (ECG) was recorded before and 28 days
after the first dose. Adverse events and laboratory results were
graded, where applicable, according to the WHO recommenda-
tions for grading acute and subacute toxic effects (WHO, 1979).
Sa l iiehods
The primary end points were AUCo: and AUCQkk and the
secondary end points were C. and t,. These paraneters were
compared between groups ofpatients using analysis ofcovariance.
Because there was an imbalance in the numbers ofmen and women
in the two renal function groups (see Table 1), each end point was
analysed in two stages. The first stage examined the effects ofrenal
function and the second the effects of gender. Both analyses were
adjusted for age and weight at entry. AUC(-, AUCos& and C,
were log transformed before analysis. The analysis results were
back-transformed andpresented as adjustedgeometric least squares
means (glsmeans), and ratios (impaired-normal renal function.
female-male) with 95% confidence limits and associated P-values.
The t,r was not log transformed, and the analysis results were
Tabe 1 Patient characteriscs at entry
NonN ed
fnct f k
No. of patients 8 8
Sex (no. and % of patients)
Women 1 (13%) 7 (88%)
Men 7(88%) 1 (13%)
Age (years; mean and range) 60 (44-71) 58 (33-68)
Weight (kg; mean and range) 75 (63-84) 66 (49-93)
Height (cm; mean and range) 174 (161-181) 164 (150-177)
Primary tumour (no. and % of patients)
Cokoectal 7 (88%) 1 (13%)
Ovary 0 3 (38%)
Breast 0 1(13%)
Carcinoma of unknown ongin 0 2 (25%)
Mesotheoma 1 (13%) 0
Synovia sarcoma 0 1 (13%)
Previous d hrapy (no. and % patents)
None 3(38%) 0
Plabinum-containing regimes 1 (13%) 5 (63%)
Ifosfmi-as regimens 0 1 (13%)
Other 4 (50%) 2 (25%)
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Table 2 Ralttrexed pharmacolunetic parameters (means; standard
deviations)
Parameter Normal renal function Impaired renal function
(n=8) (n=8)
C, (ng mt-1) 567.1 ± 62.7 676.1 + 204.1
AUC(,._ (ng h mV) 1355.8 ± 558.5 2522.0 ± 784.9
AUCO_ (ng h mht) 1547.9 ± 521.7 3414.5 ± 2510.5
t. (min) 16 (15-20)a 20 (10-30)a
t,25 (h) 1.82 ± 1.30 1.79 ± 0.49
tt, (h) 140.0 ± 55.0 274.5 ± 127.4
Clearace(ml min-,) 66.7 ± 21.7 32.3 ± 12.3
Volume of distribution (I) 7.3 ± 3.0 6.2 ± 2.4
Volume of distribution at 492.8 ± 197.5 493.0 ± 100.3
steady state (I)
aMedian and range. tidc, time to last determined concentration.
presented as adjusted least squares means (Ismeans). and differ-
ences (impaired minus normal renal function. female minus male)
with 95% confidence limits and associated P-values.
RESULTS
Patients
The characteristics of the patients recruited onto the study are
listed in Table 1.
Pharmacokinetics
Single-dose pharmacokinetics
All 16 patients were included in the pharmacokinetic analysis.
Mean raltitrexed pharmacokinetic parameters for the patients with
normal renal function and the patients with renal impairment are
presented in Table 2. Peak concentrations ofraltitrexed were found
in the samples taken either immediately before or immediately
after the end of the infusion for all patients except one, for whom
tMa occurred at 6 mmn before the end ofthe infusion. In both groups
of patients. plasma concentrations of raltitrexed declined triexpo-
nentially after the peak and could be described using a three-
compartment pharmacokinetic model (Figures 1 and 2). The t
was between 30 mmi and 12 h after the end of the infusion and the
terminal phase was from 24 h onwards (Figure 2). The terminal
phase accounted for approximately two-thirds of the AUC for the
patients with normal renal function and approximately three-
quarters ofthe AUC for the patients with renal impairment.
Mean AUC,,andAUCc, were approximately double for the
patients with renal impairment compared with those with normal
renal function (Table 3). The analysis of covariance showed a
statistically significant difference between the groups for both
AUCo (P = 0.002) and AUC, (P = 0.008). The difference in
CmL values between the groups was not statistically significant
(P = 0.204). but tl , was statistically significantly longer in the
group with renal impairment (P = 0.030).
The relationship between raltitrexed clearance and calculated
creatinine clearance is depicted in Figure 3 [creatinine clearance
was calculated using Cockcroft's equation (Cockcroft and Gault.
1976)]. The calculated creatinine clearance was used because two
patients in the normal renal function group did not have a
["Cr]EDTA creatinine clearance before treatment. In addition. the
['ICr]EDTA method of determininga creatinine clearance is not
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Figure 1 Mean plasma cocntrations up to 12 h after administration of
raltitrexed 3.0 mg m 2 to patients with normnal renal function and patients wfit
renal impairrnent
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Figure 2 Mean plasma concentrations up to 28 days after administration of
raltirexed 3.0 mg in-2 to patients with normal renal functon and patients with
renal impairmlent
universally available. This figure shows a clear relationship
between the two variables, with raltitrexed clearance decreasing
with increasingly severe renal impairment. This was also true
when raltitrexed clearance was compared with EDTA creatinine
clearance (Figure 4).
The large volume at steady state (V*) compared with the volume
of the central compartment (V). coupled with the long rl>
suggtests that there is a third compartment that strongaly binds
raltitrexed. Modelled pharmacokinetic data showed that the longa
t,>is controlled by slow retumn of raltitrexed to the central
compartment from a deep tissue compartment or binding site. In
the model. the microrate constant for return from the third
compartment to the central compartment was smaller than the
microrate constant for the elimination of raltitrexed from the
central compartment. This is consistent with the slow release of
raltitrexed from intracellular sites following hydrolvsis of its
polyglutamated forms. Raltitrexed concentrations in the second
and third compartments at steady state mirrored the t, 1
Simulated multiple dosing
The effects of multiple dosing were simulated using the three-
compartment mo>del that was used to fit the data. The mean microrate
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Table 3 Statistical analysis of the effect of renal impairment on ralttrexed C,, AUC and t,2
Renal function gisfIs Estimated 95% Confidence P-value
mean ratio/difference limits
(impaired normnal)
C, (ng ml-) Normal 564.7 1.16 0.91-1.46 0.204
Impaired 652.9
AUC__ (ng.h m-') Normal 1457.0 2.03 1.25-3.29 0.008
Impaired 2961.5
AUC, _. (ng.h mVt) Normal 1247.6 1.97 1.36-2.84 0.002
Impaired 2452.2
t2. (h) Normal 143.3 127.9a 14.3-241.5 0.030
Impaired 271.2
aDifference (impaired renal function minus normal renal function) for t, ,,. glsAs mean, geormetric leastsquares/least squares mean.
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Figure 3 Relationship between plasma clearance of ralttrexed and
calculated creatinine clearance in patients with normal renal furnton and
patients with renal impairment
constants from the pharmacokinetic model from each group were
used to predict plasma concentrations ofraltitrexed after administra-
tion of six doses at 3.0 mg m '. each 3 weeks apart.
For the group with normal renal function. simulated C
' values
remained almost constant at 509 ng ml-' over all six doses. The
predicted trough concentrations of raltitrexed (i.e. at 504 h after
dosing) increased from 0.29 to 0.31 ng ml-': both these values are
below the limit ofquantification ofthe assay (0.768 ng ml- ).
For the patients with renal impairnent. the simulated C ^ was
606 ncg ml 'after the first dose and 608 ng ml-' after the sixth dose.
The predicted trough concentrations of raltitrexed increased by
30%7. from 1.2 to 1.6 ng ml-' over the six doses. Most of this
increase occurred after the second dose and steady state had appar-
ently been reached by the fourth dose. However. the predicted
increase in concentration was approximately equal to the inter-
patient vanability in plasma concentrations at 3 weeks afterdosing.
Safety
Exposure to raltitrexed
Ten patients (six with normal renal function. four with renal
impairment) continued raltitrexed treatment after the first dose. A
total of 26 doses (range 1-6 doses) were administered to patients
with normal renal function and 13 doses (range 1-3 doses) were
Figure 4 Relationship between plasma clearance of raltitrexed and
F1Cr]EDTA cleararce in patients with normal renal function and patients with
renal impairment
administered to patients with renal impairment. Three patients
(one with normal and two with impaired renal function) received a
reduced dose of raltitrexed as a result of haematological and/or
gastrointestinal toxicity during previous cycles.
Adverse events and WHO-graded toxicity
The WHO grades for adverse events and laboratory results. irre-
spective of the causality of the events, are summarized in Table 4.
Asthenia was the only significant adverse exvent to be reported that
is not included in the WHO grading system. For patients with
normal renal function. the most frequently observed adverse
events or laboratory abnormnalities were anaemia. increased
concentrations of alkaline phosphatase. asthenia and infection
(oral candidiasis. urinary tract infection). For the group with renal
impairment. the most frequently reported toxicities were nausea
and xomitin. anaemia and fever. Eight patients (two with normal
and six with impaired renal function) were hospitalized as a result
ofadverse events.
No WHO grade 3 or 4 drug-related toxicity was reported for
patients with normal renal function. In contrast, grade 3 or4 toxicity
was observed in the group with renal impairnent. One renally
impaired patient developed grade 4 haematological suppression
and infection with grade 3 diarrhoea. mucositis and exfoliative
dermatitis. and subsequently died. One patient with cellulitis at entiv
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Table 4 Adverse events and laboratory abnormalities graded according to WHO recomrmendatons
Number of Paient (%)
Effect Normal renal function Impaired renal function
(n=8) (n=8)
Grade 3 or 4 TotaP Grade 3 or4 TotaP
Laboratory results
Haemoglobin 0 7 (88%) 1 (13%) 5 (63%)
Leucocytes 0 0 1 (133%) 1 (13%)
Neutrophils 0 0 1 (13%) 1 (13%)
Platelets 0 0 1 (13%) 1 (13%JO)
Transaminases 0 3 (38%) 0 1 (13%)
Alkaline phosphatase 0 5 (63%) 0 1 (13%o)
Urea or creatine 0 1 (13%) 0 3 (38%)
Adverse events
Haemorrhage 0 0 0 1(13%)
Oral (mucositis) 0 1 (13%) 1 (13%) 2 (25%)
Nausea and vomiting 0 2 (25%) 1 (13%) 5 (63%)
Diarrhoea 1 (13%)c 3 (38%) 2 (25%) 3 (38%)
Pulmonary 0 0 1 (133%) 1 (13%)
Fever 0 1 (13%) 0 4 (500o)
Cutaneous 0 0 1 (13%/o) 1 (13%)
Infection 0 4 (50%0/6) 2 (25%) 3 (38%)
Cardiac rhythm 0 0 0 1 (13%)
Constipation 0 0 0 1 (13°h)
Pain O O O 3 (38%)
Astheniat NA 4 (50%) NA 3 (380o)
aTotal number ofWHO graded events. 'Graded as mild, moderate or severe; there were no cases of severe asthenia. cNot considered
drug related by the investgator. NA, not applicable.
Table 5 Renal functi, pharmacokinetc parameters and toxicity for patients with renal impairment
Cr-EDTA Calcuated AUCo-, t (h) Worst grade of Worst grade of Serious adverse
clearance creatinine clearance (ng.h mIl-) gastrointestinal haematological events
(ml min-) (ml min-) toxicity toxicitt
28 23.2 3727.0 578.7 Grade 3 Grade 4 Death
30 26.5 3395.3 263.2 Grade 2 None Asthenia, flu
syndrome.
abdominal pain
46 58.1 1795.8 187.7 Grade 4 Grade 3 Diarrhoea,
anaemia
47 53.3 2315.8 208.5 None None Chest pain,
dyspnoea,
anaemia
49 51.8 1733.7 207.9 Grade 2 None Abdominal
pain.
confusion,
hallucinations
51 47.5 1663.7 209.1 Grade 2 None Diarrhoea
57 52.9 2623.3 284.8 Grade 2 None Cellulitis
63 54.0 2921.4 256.5 None None Asthenia
aLeucopenia, neutropenia orthrombocytopenia.
to the trial was reported to have grade 3 infected cellulitis. Other
grade 4 toxicities included vomiting (one patient). diarrhoea (one
patient) and dyspnoea (one patient). The patient with dyspnoea also
had chest pain and haemoptysis. and was thought to have a
pulmonary embolus: this was not attributed to raltitrexed treatment.
Relationships ofrenal function and toxicity
Table 5 summarizes the data conceming individual patient s renal
function. reported toxicity and pharmacokinetic parameters.
Compared with the patients with normal renal function. there was
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a higher incidence of adverse events. hospitalization because of
adverse events. and severe (grade 3 or4) toxicity in the group with
renal impairment. Whereas the group with renal impairment
appeared to tolerate raltitrexed less well than the group with
normal renal function there was no direct relationship between the
degree oftoxicity and creatinine clearance. AUC or
DISCUSSION
After a single 3.0 mg m- dose of raltitrexed. the mean peak
plasma concentration in renally impaired patients (creatinmne
clearance 25-65 ml min-') was not significantly different from
that in patients with normal renal function (creatinine clearance
> 65 ml min-'). AUC, and AUC were statistically sigmfi-
cantly greater. as a result oflower plasma clearance. in the patients
with impaired renal function. There was a direct relationship
between plasma raltitrexed clearance and creatinine clearance. As
a result of the slower clearance of raltitrexed. the terminal phase
was significantly longer in the patients with renal impairment
compared with the patients with normal renal function.
This prolongation of the t,, could lead to drug accumulation
during 3-weekly administration of raltitrexed. and a simulation of
dosing at 3-week intervals up to six therapy cycles suggested that
some accumulation may occur in patients with renal impairment.
The change in accumulation of raltitrexed in renally impaired
patients is. however. approximately equal to the interpatient van-
ability observed in raltitrexed plasma concentrations 3 weeks after
dosing. Therefore. the clinical relevance ofthis simulated accumu-
lation is unclear.
In this trial. there was an imbalance in the numbers of men and
women in the two groups (seven of the eigrht patients with renal
impairment were women. seven of the eight patients with normal
renal function were men). Although this was an unfortunate
imbalance. the aetiology of renal dysfunction in this group was
commonly related to the administration of cisplatin. and occurred
most frequently in women with ovarian cancer. The effect ofrenal
function on raltitrexed pharmacokinetics was confounded by the
unequal distribution of men and women in each study arm. and
this must be considered in the interpretation ofthe results. Because
previous trials have not provided any evidence to suggest that
gender may play a role in the excretion of raltitrexed. the current
data would suggest that the differences observed in this trial are
probably pnimarily related to renal impairment. It is recommended
that further studies be undertaken to exclude a possible gender
effect on raltitrexed clearance.
The safety profile of raltitrexed in this trial was consistent with
that seen in phase II trials. The most frequent adverse events and
laboratory abnormalities were myelosuppression. nausea and
vomiting. infection. and asthenia. With one marked exception.
raltitrexed was well tolerated by both patient groups. although. as
may be predicted. the patients with normal renal function appeared
to tolerate therapy better than patients with compromised renal
function. Overall. there was no clear relationship between pharma-
cokinetic parameters and the incidence of severe toxicity. For the
antimetabohite class of cytotoxics. this lack of relationship is not
surprising because toxicity is often not predictable from pharma-
cokinetic data (EORTC PAMM Group. 1987).
In conclusion. there was a clear effect of renal impairment on
the pharmacokinetics of raltitrexed: for patients with mild to
moderate renal impairment. raltitrexed clearance w-as delayed. and
elimination half-life and AUC increased compared with the group
with normal renal function. In addition. there was some evidence
that raltitrexed at a dosage of 3.0 mg m- every 3 weeks was less
well tolerated by the patients with impaired renal function. These
results suggest that a reduction in raltitrexed dose and an increased
interval between doses is recommended for patients with mild to
moderate renal impairment. The dose of raltitrexed should be
reduced by 50% in patients with a creatinine clearance between 25
and 65 ml mmn-' and the dosage interval be increased to 4 w-eeks.
In patients with a creatinine clearance below 25 ml min-'. the use
ofraltitrexed is not advised.
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